Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Malcolm A Smith

Showing results (11-20 of 188) with videos related to

Pageof 19
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 21, 2008
Complexities in interpretation of osteosarcoma clinical trial resultsSally Hunsberger, Boris Freidlin, Malcolm A Smith
Journal of the National Cancer Institute|June 29, 2011
More randomization in phase II trials: necessary but not sufficientLawrence Rubinstein, Michael Leblanc, Malcolm A Smith
Journal of the National Cancer Institute|April 4, 2024
Targeting fusion oncoproteins in childhood cancers: challenges and future opportunities for developing therapeuticsSharad K Verma, Keren L Witkin, Anu Sharman, et al.
Journal of the National Cancer Institute|January 25, 2026
Changing standard of care during a randomized trial: examples, considerations and guidelinesBoris Freidlin, Malcolm A Smith, Carmen J Allegra, et al.
Journal of the National Cancer Institute|April 17, 2003
Re: Views of American oncologists about the purposes of clinical trialsBarry D Anderson, Malcolm A Smith, Gregory H Reaman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2005
Preliminary data release for randomized clinical trials of noninferiority: a new proposalEdward L Korn, Sally Hunsberger, Boris Freidlin, et al.
Oncology (Williston Park, N.Y.)|May 9, 2003
Clinical trials referral resource. Current clinical trials of imatinib mesylateAnthony J Murgo, Kimberly F Wood, Mason Schoenfeldt, et al.
Clinical Trials (London, England)|August 14, 2008
Comments on 'maintaining confidentiality of interim data to enhance trial integrity and credibility' by TR Fleming et alEdward L Korn, Sally Hunsberger, Boris Freidlin, et al.
Oncology (Williston Park, N.Y.)|March 30, 2004
Clinical trials referral resource. Current clinical trials of molecularly targeted agents in children with cancerMalcolm A Smith, Anthony J Murgo, John J Wright, et al.
Pediatric Blood & Cancer|October 22, 2020
In vivo evaluation of the EZH2 inhibitor (EPZ011989) alone or in combination with standard of care cytotoxic agents against pediatric malignant rhabdoid tumor preclinical models-A report from the Pediatric Preclinical Testing ConsortiumRaushan T Kurmasheva, Stephen W Erickson, Eric Earley, et al.
Pageof 19

Showing results (11-20 of 188) with videos related to

Sort By:
Pageof 19
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 21, 2008
Complexities in interpretation of osteosarcoma clinical trial resultsSally Hunsberger, Boris Freidlin, Malcolm A Smith
Journal of the National Cancer Institute|June 29, 2011
More randomization in phase II trials: necessary but not sufficientLawrence Rubinstein, Michael Leblanc, Malcolm A Smith
Journal of the National Cancer Institute|April 4, 2024
Targeting fusion oncoproteins in childhood cancers: challenges and future opportunities for developing therapeuticsSharad K Verma, Keren L Witkin, Anu Sharman, et al.
Journal of the National Cancer Institute|January 25, 2026
Changing standard of care during a randomized trial: examples, considerations and guidelinesBoris Freidlin, Malcolm A Smith, Carmen J Allegra, et al.
Journal of the National Cancer Institute|April 17, 2003
Re: Views of American oncologists about the purposes of clinical trialsBarry D Anderson, Malcolm A Smith, Gregory H Reaman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2005
Preliminary data release for randomized clinical trials of noninferiority: a new proposalEdward L Korn, Sally Hunsberger, Boris Freidlin, et al.
Oncology (Williston Park, N.Y.)|May 9, 2003
Clinical trials referral resource. Current clinical trials of imatinib mesylateAnthony J Murgo, Kimberly F Wood, Mason Schoenfeldt, et al.
Clinical Trials (London, England)|August 14, 2008
Comments on 'maintaining confidentiality of interim data to enhance trial integrity and credibility' by TR Fleming et alEdward L Korn, Sally Hunsberger, Boris Freidlin, et al.
Oncology (Williston Park, N.Y.)|March 30, 2004
Clinical trials referral resource. Current clinical trials of molecularly targeted agents in children with cancerMalcolm A Smith, Anthony J Murgo, John J Wright, et al.
Pediatric Blood & Cancer|October 22, 2020
In vivo evaluation of the EZH2 inhibitor (EPZ011989) alone or in combination with standard of care cytotoxic agents against pediatric malignant rhabdoid tumor preclinical models-A report from the Pediatric Preclinical Testing ConsortiumRaushan T Kurmasheva, Stephen W Erickson, Eric Earley, et al.
Pageof 19